Literature DB >> 27405668

Rethinking events in the haemostatic process: role of factor V and TFPI.

R M Camire1.   

Abstract

Regulatory mechanisms responsible for limiting blood clot formation are critical for maintaining normal haemostasis. Dysregulation can lead to bleeding (e.g. haemophilia) or thrombosis. New findings showing that tissue factor pathway inhibitor-alpha (TFPIα) binds coagulation factor V(a) and inhibits prothrombinase assembly highlights that our understanding of the initiation of coagulation is evolving. Work over the past decade on the biochemistry of FV activation has laid the groundwork for deciphering the mechanistic bases that may underpin how TFPIα mediates these anticoagulant effects. Collectively, these new findings are re-shaping our thinking about how coagulation is initiated at the site of injury. These ideas could have important clinical implications and help identify new ways to bias the coagulation response for the treatment of haemophilia and other disorders of the haemostatic process.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  TFPI; bleeding disorders; coagulation; factor V; factor Va; haemophilia

Mesh:

Substances:

Year:  2016        PMID: 27405668     DOI: 10.1111/hae.13004

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  Novel approaches to hemophilia therapy: successes and challenges.

Authors:  Valder R Arruda; Bhavya S Doshi; Benjamin J Samelson-Jones
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

2.  Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency.

Authors:  Dino Mehic; Alexander Tolios; Stefanie Hofer; Cihan Ay; Helmuth Haslacher; Judit Rejtö; Willem H Ouwehand; Kate Downes; Matthias Haimel; Ingrid Pabinger; Johanna Gebhart
Journal:  Blood Adv       Date:  2021-01-26

3.  Effects of Saccharides from Arctium lappa L. Root on FeCl3-Induced Arterial Thrombosis via the ERK/NF-κB Signaling Pathway.

Authors:  Tiantian Qiu; Hailun Zhou; Suying Li; Nuoya Tian; Zhe Li; Rui Wang; Pengyuan Sun; Jinyong Peng; Jianling Du; Xiaochi Ma; Yunpeng Diao; Li Lv; Li Wang; Hua Li
Journal:  Oxid Med Cell Longev       Date:  2020-03-24       Impact factor: 6.543

Review 4.  Platelets, Constant and Cooperative Companions of Sessile and Disseminating Tumor Cells, Crucially Contribute to the Tumor Microenvironment.

Authors:  Wolfgang M J Obermann; Katrin Brockhaus; Johannes A Eble
Journal:  Front Cell Dev Biol       Date:  2021-04-16

5.  A hydrophobic patch (PLVIVG; 1481-1486) in the B-domain of factor V-short is crucial for its synergistic TFPIα-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIα, and protein S.

Authors:  Björn Dahlbäck; Sinh Tran
Journal:  J Thromb Haemost       Date:  2022-03-16       Impact factor: 16.036

Review 6.  Pathophysiological Aspects of Aging in Venous Thromboembolism: An Update.

Authors:  Dimitra Akrivou; Garifallia Perlepe; Paraskevi Kirgou; Konstantinos I Gourgoulianis; Foteini Malli
Journal:  Medicina (Kaunas)       Date:  2022-08-10       Impact factor: 2.948

7.  Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis.

Authors:  Maria Elisa Mancuso; Sheila J M Ingham; Marc Kunze
Journal:  Haemophilia       Date:  2022-06-06       Impact factor: 4.263

8.  A clinically relevant and bias-controlled murine model to study acute traumatic coagulopathy.

Authors:  C Gangloff; O Grimault; M Theron; K Pichavant; H Galinat; F Mingant; Y Ozier
Journal:  Sci Rep       Date:  2018-04-10       Impact factor: 4.379

9.  Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.

Authors:  Björn Dahlbäck; Li Jun Guo; Ruzica Livaja-Koshiar; Sinh Tran
Journal:  Res Pract Thromb Haemost       Date:  2017-12-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.